Navigation Links
Ardea Biosciences to Present at Roth Capital Partners' 20th Annual OC Growth Stock Conference
Date:2/12/2008

CARLSBAD, Calif., Feb. 12 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that Barry D. Quart, PharmD, President and CEO of Ardea Biosciences, will present at the Roth Capital Partners' 20th Annual OC Growth Stock Conference.

Date: Tuesday, February 19, 2008

Time: 4:00 p.m. Pacific Time

Location: The Ritz Carlton Laguna Niguel, Dana Point, CA

Webcast: http://www.wsw.com/webcast/roth16/rdea/ or

http://www.ardeabio.com

About Ardea Biosciences, Inc.

Ardea Biosciences of Carlsbad, California is a biotechnology company focused on the discovery and development of small-molecule therapeutics in virology, oncology and inflammation. The Company has two product candidates in clinical development and several others in preclinical development. Ardea's most advanced clinical development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. In addition, the Company is also investigating RDEA806 for the treatment of gout. In oncology, the Company is investigating a mitogen-activated ERK kinase (MEK) inhibitor, RDEA119, in a Phase 1 study in advanced cancer patients. Ardea also is developing a next-generation NNRTI for HIV and a next-generation MEK inhibitor for both cancer and inflammatory diseases.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, ac
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
2. Ardea Biosciences Announces Changes to Research Management
3. Ardea Biosciences, Inc. Reports Third Quarter 2007 Operating and Financial Results
4. Ardea Biosciences to Participate in RBC Capital Markets 2007 Healthcare Conference
5. Ardea Biosciences Announces $40 Million Private Placement
6. Ardea Biosciences to Present Preclinical Data on Three HIV Non-Nucleoside Reverse Transcriptase Inhibitors During 15th Annual Conference on Retroviruses and Opportunistic Infections
7. Ardea Biosciences Establishes Scientific Advisory Board for HIV Program
8. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
9. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
10. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
11. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... OAK RIDGE, Tenn., July 24, 2014 -- A novel ... at the Department of Energy,s Oak Ridge National Laboratory ... known for its unusual physical and electrochemical properties. ... examined how oxygen affects the surface of a perovskite ... electronic behavior. The new avenue to understand surface behavior ...
(Date:7/24/2014)... Security forces worldwide rely on sophisticated equipment, trained ... other public areas against terrorist attacks. A revolutionary ... about to make their job much easier. , ... Patolsky of Tel Aviv University ,s School of ... developed by the Herzliya company Tracense, picks up ...
(Date:7/24/2014)... DUBLIN , July 24, 2014 ... the "Global Cell Culture Market 2014-2018" report ... Cell culture is the in vitro ... such as research, cell studies, and biopharmaceutical production. Cell ... vaccine production. Cell culture instruments and cell culture consumables ...
(Date:7/24/2014)... Three companies from the angelMD network ... C Competition. Out of 700 competition entrants, Chiron Health, ... semi-final round. In this round twenty teams are invited ... with mentoring from thought-leaders and medical entrepreneurs from all ... angelMD commitment to the Livestrong vision around the Big ...
Breaking Biology Technology:ORNL study reveals new characteristics of complex oxide surfaces 2Nano-sized chip 'sniffs out' explosives far better than trained dogs 2Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 23 angelMD Startups Make Livestrong Big C Semi-finals 2
... Spherix,Incorporated (Nasdaq: SPEX ) reported a net ... The Company,s research and development costs,jumped to $5.9 million ... of,the Company,s Phase 3 clinical trial for Naturlose as ... trial is expected to last at least two years,and ...
... Meets LEEDS Standards for Sustainable Development, PLEASANTON, ... today announced the opening of its new research ... The,building represents the final phase of consolidation of ... which now houses close to 500,employees, including 120 ...
... Ratcliff, the,award-winning architecture, planning and interiors firm, ... care tower,accompanied by a 767-stall parking garage and ... - Walnut Creek Campus. The Thomas J.,and Muriel ... ground will add,230 private and six semi-private rooms, ...
Cached Biology Technology:Spherix Reports 2007 Financial Results 2Roche Molecular Diagnostics Invests $57.5 Million in 'Green' Research Building 2Roche Molecular Diagnostics Invests $57.5 Million in 'Green' Research Building 3Ratcliff Designs Hospital of the Future for John Muir Medical Center - Walnut Creek Campus 2Ratcliff Designs Hospital of the Future for John Muir Medical Center - Walnut Creek Campus 3
(Date:7/24/2014)... 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") ... active control Phase 3 study of Zerenex (ferric citrate), ... the treatment of hyperphosphatemia in patients with end-stage renal ... and iRon delivery with FErric CiTrate in EsrD) was ... American Society of Nephrology ( JASN ). ...
(Date:7/24/2014)... numbers have decreased by 45% on average over a ... reports a study on the impact of humans on ... enormous benefits invertebrates such as insects, spiders, crustaceans, slugs ... and pest control for crops, decomposition for nutrient cycling, ... in Science and led by UCL, Stanford ...
(Date:7/24/2014)... the product of 3.5 billion years of evolutionary trial ... life. But it may be reaching a tipping point. ... analysis of data published in Science , an ... decline of animals is contributing to what appears to ... biological extinction event. , Since 1500, more than 320 ...
Breaking Biology News(10 mins):Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4Invertebrate numbers nearly halve as human population doubles 2Invertebrate numbers nearly halve as human population doubles 3Stanford biologist warns of early stages of Earth's 6th mass extinction event 2Stanford biologist warns of early stages of Earth's 6th mass extinction event 3
... online citizen-science project launches called "Plankton Portal" ... Rosenstiel School of Marine and Atmospheric Sciences (RSMAS) in ... and the National Science Foundation (NSF) and developers at ... ocean from the comfort of your own home. You ...
... two typhoons over a three-week period in August, ... partnership with the Okinawa Institute of Science and ... OceanCube Observatory System in waters off Motobu Peninsula, ... to ecologically significant coral reefs. The observatory system ...
... research group from Singapore, scientists at University of Copenhagen ... of truncated O-glycans aid growth properties of cancer cells. ... significance of these truncated O-glycans, and therefore, the results, ... , represent an important contribution to understanding the growth ...
Cached Biology News:Online citizen scientists: Classify plankton images 2Establishing world-class coral reef ecosystem monitoring in Okinawa 2Establishing world-class coral reef ecosystem monitoring in Okinawa 3Specific sugar molecule causes growth of cancer cells 2
... Useful as a positive control for ... to chromatin in vivo is a crucial ... extent of crosslinking is probably the most ... subsequent immunoprecipitation step should be taken into ...
Mouse monoclonal [M2II-12] to MRP2 ( Abpromise for all tested applications). entrezGeneID: 1244 SwissProtID: Q92887...
The Programmable MP-5000P-F Power Supply can be applied for any Microfluidic application....
Rab GDP dissociation inhibitor beta...
Biology Products: